ClinicalTrials.gov
public full text
Public Domain
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
The purpose of this open-label study is to assess the efficacy and safety of a novel treatment algorithm for sequencing remibrutinib and omalizumab in the treatment of adult participants with chronic spontaneous urticaria (CSU) who are inadequately controlled by second-generation H1-antihistamines (sgH1-AH).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria#877113
- Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria#1010967
- A Study of Efficacy and Safety of TLL-018 in CSU Participants#910777
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria#1075763
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients#1088524
Record · ID 871349
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive